Research Study

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT02207231
Status 
Closed to Recruitment
Study Start/End 
Dec 1, 2014 to May 31, 2018
Locations 
Vancouver General Hospital
Name/Title 
Satvir Dhoot, Clinical Trial Coordinator
Phone 
604-875-5296
Email Address 
satvir.dhoot@ubc.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.